Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
10 jul 2006 - 08:14
Statutaire naam
Crucell N.V.
Titel
Crucell and DSM Biologics Announce Invitrogen as First Partner in PER.C6® Vendor Network
Bericht
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics have announced today that Invitrogen, a leading life sciences products and services provider, will become the first company to enter the partnership’s PER.C6® licensing business Vendor Network for monoclonal antibodies and recombinant proteins.
Datum laatste update: 21 december 2025